<DOC>
	<DOCNO>NCT01863758</DOCNO>
	<brief_summary>To compare number breakthrough bleeds tailor prophylaxis human cell line recombinant factor FVIII ( Human-cl rhFVIII ) historical bleeding rate patient receive Human-cl rhFVIII demand treatment .</brief_summary>
	<brief_title>Assess Safety Efficacy Individually Tailored Prophylaxis With Human-cl rhFVIII Patients With Severe Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe Haemophilia A ( FVIII : C &lt; 1 % ) accord medical history Male patient &gt; = 18 year Previous treatment FVIII concentrate ( regular prophylaxis good compliance ondemand treatment ) least 150 Exposure Days ( EDs ) Good documentation regard dose bleeding frequency 6 month precede study start Immunocompetence ( CD4+ count &gt; 200/microliter ) HIVnegative , positive , viral load &lt; 200 particles/microliter &lt; 400,000 copies/mL Any coagulation disorder Haemophilia A Present past FVIII inhibitor activity ( &gt; 0.6 BU ) Severe liver kidney disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>